Since Shlomo Yanai became president and CEO in March 2007, Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) has been reconfigured from a company in which generics and the U.S. market provided the lion's share of the top line. In 2006, 60% of $8.4 billion in worldwide sales came from North America, 26% from Europe and 14% from